Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474081 · ClinicalTrials.gov registry record · Phase 4
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 800
- Enrollment target
NCT03474081 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 800 participants.
The verdict
NCT03474081, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 800 participants
- Enrollment target
Study Summary
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing. Once-daily triple therapy of an Inhaled Corticosteroid/ Long-acting Muscarinic Receptor Antagonists/ Long Acting Beta-Agonist (ICS/LAMA/LABA) that is combination of FF/UMEC/VI in a single device is being developed with the aim of providing a new treatment option for the management of advanced COPD. The primary purpose of this study is to evaluate lung function and health related quality of life (HRQoL) after 84 days of treatment with a single inhaler triple therapy combination of FF/ UMEC/VI once daily via the ELLIPTA® dry powder inhaler (DPI) compared with tiotropium once daily via HANDIHALER®, in subjects with COPD. Subjects will be randomized 1:1 to receive FF/UMEC/VI or tiotropium in the morning for 84 days. Subjects will also receive albuterol/salbutamol as a rescue therapy throughout the study. Approximately 848 subjects with advanced COPD will be enrolled in the study. The total study duration will be approximately 17 weeks including, 4-week run-in period, 12-week treatment period and a 1-week follow-up period. ELLIPTA is a registered trademark of GlaxoSmithKline (GSK) group of companies. HANDIHALER and RESPIMAT are registered trademarks of Boeringher Ingelheim.
Interventions
- DRUG FF/UMEC/VI
- DRUG Tiotropium
- DRUG Albuterol/salbutamol
- DRUG Placebo to match FF/UMEC/VI
- DRUG Placebo to match tiotropium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03474081
The ClinicalTrials.gov registry entry for NCT03474081 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which FF/UMEC/VI is the first listed.
NCT03474081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03474081 about?
NCT03474081 is a clinical study titled "A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing. Once-daily triple therapy of an Inhaled Corticosteroid/ Long-acting Muscarinic Receptor...
What is the current status of trial NCT03474081?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 800 participants. The study started on 2018-03-29. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT03474081?
The interventions under investigation include: FF/UMEC/VI (DRUG), Tiotropium (DRUG), Albuterol/salbutamol (DRUG), Placebo to match FF/UMEC/VI (DRUG), Placebo to match tiotropium (DRUG).
Who is sponsoring clinical trial NCT03474081?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.